Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escherichia coli nissle 1917 (Ardeypharm)
- Development stage
- Unknown
- Lead developer
- Ardeypharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Mutaflor is a probiotic pharmaceutical containing the live, non-pathogenic strain *Escherichia coli* Nissle 1917 (EcN). [2, 5] First isolated in 1917, it is one of the most extensively studied probiotics worldwide. [1] Mutaflor is used for the treatment and management of various gastrointestinal disorders, most notably for maintaining remission in ulcerative colitis and for managing chronic constipation. [3, 7, 8] It is available as enteric-coated capsules and a suspension for oral use. [2, 7] The mechanism of action is multifaceted, involving the modulation of the gut microbiome, competitive exclusion of pathogens, production of antimicrobial substances, enhancement of the intestinal barrier function, and immunomodulatory effects, including the down-regulation of pro-inflammatory cytokines. [1, 2, 5] Clinical studies have shown its efficacy in maintaining remission in ulcerative colitis is comparable to standard mesalamine therapy. [15] The drug is developed and manufactured by Ardeypharm. [14]
- Brand names
- Mutaflor
- Other names
- Escherichia coli strain Nissle 1917
Beyond the preview
Go deeper on escherichia coli nissle 1917 (Ardeypharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escherichia coli nissle 1917 (Ardeypharm).